Improve allo-SCT transplant outcome using a uniform conditioning regimen and pacritinib pretreatment by means of the proportion of patients with a failure within 6 months post-transplant Events that are considered a failure are: primary graft failure secondary graft failure acute GvHD grade 3-4 death whatever the cause is
Data and Resources
- A phase II trial in patients with myelofibrosis primary post-ET or post PV-MF treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantationjson
Improve allo-SCT transplant outcome using a uniform conditioning regimen and...
|Release Date|| |
|Public Access Level|| |